Rebecca joined atai Life Sciences in 2022. Previously, Dr. Aron was Head of Neurobiology at Sensorium Therapeutics where she was responsible for strategy development for the neuropsychiatric program and platform biology activities. Prior to that, she was Sr. Principal Scientist at Triplet Therapeutics where she was a Cell and Molecular Biology team manager, and program leader for target validation and therapeutic discovery for neurodegenerative disorders. Dr. Aron also held R&D positions at Pfizer, Aquinnah Pharmaceuticals, and Yumanity Therapeutics.
Dr. Aron holds BS and MS degrees in Biochemistry and Molecular Biology from the University of Massachusetts Amherst, a Ph.D. in Biomolecular Chemistry from the University of Wisconsin Madison, and conducted her postdoctoral training in Neuroscience at the Gladstone Institutes affiliated with the University of California San Francisco.